George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 Apr 11. doi: 10.1007/s41669-024-00483-w
Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7
Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3
Hill NL, Mogle J, Bhargava S, Bratlee-Whitaker E, Wion RK, Sweeder L, Sliwinski M, Barnes LL. Within-person associations among self-perceptions of memory, depressive symptoms, and activity participation in older adults. Gerontologist. 2021 Sep 13;61(7):1107-17. doi: 10.1093/geront/gnaa208
Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Hill NL, Mogle J, Whitaker EB, Gilmore-Bykovskyi A, Bhargava S, Bhang IY, Sweeder L, Tiwari PA, Van Haitsma K. Sources of response bias in cognitive self-report items: "Which memory are you talking about?". Gerontologist. 2019 Sep 17;59(5):912-24. doi: doi.org/10.1093/geront/gny087